OmniAb outlines $35M-$39M 2026 revenue outlook, backed by Eli Lilly deal and xPloration doubling plan (NASDAQ:OABI)
· seekingalpha.com
OmniAb Q3 2026 earnings insights: Lilly deal, raised revenue guidance, and xPloration growth plans.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...